BioSpace News Archive

Second Phase 3 trial undertaken in collaboration with NIAID to announce results , both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection

Immunotherapy assay enables determination of PD-L1 status in significant proportion of patients and could guide personalised treatment selection

An acceleration of development in order to advance the marketing horizon up to 3 years, to conquer an addressable market of over one billion euros

SciBase Holding AB [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced the publication of a new clinical study supporting SciBase’s strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms.

Vanderbilt University Medical Center is actively enrolling volunteers in an ongoing clinical treatment study for adults with COVID-19.

Crown Aesthetics, a division of Crown Laboratories, Inc., is delighted to announce that SkinPen Precision, the first microneedling device cleared by the FDA and the gold standard for skin remodeling technology, now has a direct presence in the UK and Ireland.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus, announced the poster presentation of Seneca Therapeutics’ abstract titled “Oncolytic Seneca Valley Virus overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV”.

Yiling Pharmaceutical released its 2020 annual report on Thursday. It achieved an operating revenue of RMB 8.782 billion in 2020, with a year-on-year growth of 50.76%; and net profit attributed to equity holders of RMB 1.219 billion, with a year-on-year growth of 100.95%.

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the presentation of a poster highlighting preclinical BP1002 data at the 2021 American Association for Cancer Research (AACR) Annual Meeting.

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, announced it will design, manufacture, and install multiple 4,000L fermenter trains for HEC Pharm’s manufacturing site in Guangzhou, China.